Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Toxins (Basel) ; 13(5)2021 05 17.
Artigo em Inglês | MEDLINE | ID: mdl-34067828

RESUMO

The primary studies have shown that scorpion analgesic peptide N58A has a significant effect on voltage-gated sodium channels (VGSCs) and plays an important role in neuropathic pain. The purpose of this study was to investigate the analgesic effect of N58A on trigeminal neuralgia (TN) and its possible mechanism. The results showed that N58A could significantly increase the threshold of mechanical pain and thermal pain and inhibit the spontaneous asymmetric scratching behavior of rats. Western blotting results showed that N58A could significantly reduce the protein phosphorylation level of ERK1/2, P38, JNK, and ERK5/CREB pathways and the expression of Nav1.8 and Nav1.9 proteins in a dose-dependent manner. The changes in current and kinetic characteristics of Nav1.8 and Nav1.9 channels in TG neurons were detected by the whole-cell patch clamp technique. The results showed that N58A significantly decreased the current density of Nav1.8 and Nav1.9 in model rats, and shifted the activation curve to hyperpolarization and the inactivation curve to depolarization. In conclusion, the analgesic effect of N58A on the chronic constriction injury of the infraorbital (IoN-CCI) model rats may be closely related to the regulation of the MAPK pathway and Nav1.8 and Nav1.9 sodium channels.


Assuntos
Analgésicos/farmacologia , Peptídeos/farmacologia , Venenos de Escorpião/química , Neuralgia do Trigêmeo/tratamento farmacológico , Analgésicos/administração & dosagem , Analgésicos/isolamento & purificação , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.8/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.8/metabolismo , Canal de Sódio Disparado por Voltagem NAV1.9/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.9/metabolismo , Dor/tratamento farmacológico , Técnicas de Patch-Clamp , Peptídeos/administração & dosagem , Peptídeos/isolamento & purificação , Ratos , Ratos Sprague-Dawley , Escorpiões , Tetrodotoxina/farmacologia
3.
Biomed Pharmacother ; 106: 930-940, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30119265

RESUMO

BACKGROUND: Oxaliplatin-induced cold allodynia is a frequent complication appearing in patients treated with this anti-tumor drug. Since, there are no clear algorithms to overcome this painful condition effectively, it is important to establish novel strategies for its treatment. AIM: In this study, the ability of pregabalin and ambroxol, used as single drugs or in combinations administered in a time-shifted manner to attenuate cold allodynia was assessed in the mouse cold plate test. The hot plate test was additionally used to assess antinociceptive properties of ambroxol in the acute, thermally-induced pain model. Locomotor activity and motor coordination of mice were also evaluated. In silico studies were undertaken to predict potential binding of ambroxol to sodium channel (Nav) subtypes whose overexpression is implicated in the development of oxaliplatin-induced neuropathic pain. KEY FINDINGS: A hyperadditive antiallodynic effect of combined sub-analgesic ambroxol and pregabalin was demonstrated in oxaliplatin-treated mice. This effect was particularly strong when these drugs were given 4 h apart. Both drugs used in combination reduced animals' locomotor activity, but they did not impair motor coordination in the rotarod test. Ambroxol did not show antinociceptive properties in the hot plate test. The molecular docking studies predicted that in mice ambroxol might bind to Nav1.6 and Nav1.9 rather than Nav1.7 and Nav1.8. SIGNIFICANCE: Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin effectively attenuates oxaliplatin-induced cold allodynia. Molecular docking model predicts preferential binding of ambroxol to mouse Nav1.6, Nav1.9 channels. This mechanism, if confirmed in vitro, might explain pharmacological activities observed in vivo.


Assuntos
Ambroxol/administração & dosagem , Analgésicos/administração & dosagem , Temperatura Baixa , Hiperalgesia/prevenção & controle , Canal de Sódio Disparado por Voltagem NAV1.6/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.9/efeitos dos fármacos , Oxaliplatina , Limiar da Dor/efeitos dos fármacos , Pregabalina/administração & dosagem , Ambroxol/metabolismo , Analgésicos/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Sítios de Ligação , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Hiperalgesia/induzido quimicamente , Hiperalgesia/metabolismo , Hiperalgesia/fisiopatologia , Masculino , Camundongos , Simulação de Acoplamento Molecular , Atividade Motora/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.6/metabolismo , Canal de Sódio Disparado por Voltagem NAV1.9/metabolismo , Ligação Proteica , Teste de Desempenho do Rota-Rod , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo
4.
Mar Drugs ; 15(9)2017 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-28867800

RESUMO

Ciguatoxins (CTXs) are marine toxins that cause ciguatera fish poisoning, a debilitating disease dominated by sensory and neurological disturbances that include cold allodynia and various painful symptoms as well as long-lasting pruritus. Although CTXs are known as the most potent mammalian sodium channel activator toxins, the etiology of many of its neurosensory symptoms remains unresolved. We recently described that local application of 1 nM Pacific Ciguatoxin-1 (P-CTX-1) into the skin of human subjects induces a long-lasting, painful axon reflex flare and that CTXs are particularly effective in releasing calcitonin-gene related peptide (CGRP) from nerve terminals. In this study, we used mouse and rat skin preparations and enzyme-linked immunosorbent assays (ELISA) to study the molecular mechanism by which P-CTX-1 induces CGRP release. We show that P-CTX-1 induces CGRP release more effectively in mouse as compared to rat skin, exhibiting EC50 concentrations in the low nanomolar range. P-CTX-1-induced CGRP release from skin is dependent on extracellular calcium and sodium, but independent from the activation of various thermosensory transient receptor potential (TRP) ion channels. In contrast, lidocaine and tetrodotoxin (TTX) reduce CGRP release by 53-75%, with the remaining fraction involving L-type and T-type voltage-gated calcium channels (VGCC). Using transgenic mice, we revealed that the TTX-resistant voltage-gated sodium channel (VGSC) NaV1.9, but not NaV1.8 or NaV1.7 alone and the combined activation of the TTX-sensitive VGSC subtypes NaV1.7 and NaV1.1 carry the largest part of the P-CTX-1-caused CGRP release of 42% and 34%, respectively. Given the contribution of CGRP to nociceptive and itch sensing pathways, our findings contribute to a better understanding of sensory symptoms of acute and chronic ciguatera that may help in the identification of potential therapeutics.


Assuntos
Ciguatoxinas/farmacologia , Canal de Sódio Disparado por Voltagem NAV1.1/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.7/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.9/efeitos dos fármacos , Receptores de Peptídeo Relacionado com o Gene de Calcitonina/efeitos dos fármacos , Animais , Peptídeo Relacionado com Gene de Calcitonina/efeitos dos fármacos , Cálcio/metabolismo , Ciguatera/metabolismo , Ciguatoxinas/química , Ensaio de Imunoadsorção Enzimática , Humanos , Hiperalgesia/induzido quimicamente , Lidocaína/farmacologia , Masculino , Toxinas Marinhas/farmacologia , Potenciais da Membrana/efeitos dos fármacos , Camundongos , Camundongos Transgênicos , Ratos , Tetrodotoxina/farmacologia
5.
Lung ; 192(1): 15-20, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24272479

RESUMO

Recent advances in our understanding of voltage-gated sodium channels (NaVs) lead to the rational hypothesis that drugs capable of selective blockade of NaV subtypes may be a safe and effective strategy for the treatment of unwanted cough. Among the nine NaV subtypes (NaV1.1-NaV1.9), the afferent nerves involved in initiating cough, in common with nociceptive neurons in the somatosensory system, express mainly NaV1.7, NaV1.8, and NaV1.9. Although knowledge about the effect of selectively blocking these channels on the cough reflex is limited, their biophysical properties indicate that each may contribute to the hypertussive and allotussive state that typifies subacute and chronic nonproductive cough.


Assuntos
Antitussígenos/uso terapêutico , Tosse/tratamento farmacológico , Canal de Sódio Disparado por Voltagem NAV1.7/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.8/efeitos dos fármacos , Neurônios Aferentes/efeitos dos fármacos , Reflexo/efeitos dos fármacos , Bloqueadores dos Canais de Sódio/uso terapêutico , Animais , Antitussígenos/efeitos adversos , Tosse/metabolismo , Tosse/fisiopatologia , Desenho de Fármacos , Humanos , Terapia de Alvo Molecular , Canal de Sódio Disparado por Voltagem NAV1.7/metabolismo , Canal de Sódio Disparado por Voltagem NAV1.8/metabolismo , Canal de Sódio Disparado por Voltagem NAV1.9/efeitos dos fármacos , Canal de Sódio Disparado por Voltagem NAV1.9/metabolismo , Neurônios Aferentes/metabolismo , Bloqueadores dos Canais de Sódio/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA